Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Pardis Sabeti—Sherlock Biosciences
Pardis Sabeti, co-founder, Sherlock Biosciences
Emergex gains new R&D facility and CSO
Wednesday, February 20, 2019
The company aims to enter the clinic with a pan-flavivirus vaccine against Zika, dengue and yellow fever in 2019.
Emergent and Valneva's Zika vaccine clears phase 1
Tuesday, November 20, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results.
J&J opens €72M vaccine plant for stepped-up R&D
Thursday, October 25, 2018
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.
Scientists weigh Zika challenge study: report
Tuesday, September 18, 2018
Zika vaccine research continues in the absence of a large-scale outbreak, but a shortage of cases is making it hard to test for efficacy.
Zika, VBI Vaccines and more—News of Note
Tuesday, August 21, 2018
Here is some other vaccine news of note for the week.
By the numbers, Sanofi’s vaccines business did quite well in 2017. Revenue grew an impressive 8.3% to reach €5.1 billion ($6.12 billion). But beyond the income statement, last year wasn’t without headline-hogging controversies and setbacks.
Platform tech bringing 'major switch' to vaccine R&D
Wednesday, March 28, 2018
Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.
Novavax talks up $1.5B sales target in RSV
Wednesday, March 21, 2018
Novavax may be years away from a potential approval of its RSV vaccine, but executives aren't waiting to prepare for a possible rollout.
Sanofi, flu vaccines and more—News of Note
Wednesday, February 28, 2018
Here's some other vaccine news of note for the week.